GLMD News and Press, Galmed Pharmaceuticals Ltd. From 05/13/25

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models PR Newswire Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment leads to significant inhibi...

2025-04-28 14:00:33 ET Plug Power Soars 32% on New $525M Credit Facility and Positive Preliminary Q1 Results Plug Power Inc. (NASDAQ: PLUG ) surged 32.45% midday to lead the PRISM Emerging New Energy Index after announcing a $525 million secured credit facility with Yorkvill...

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation PR Newswire The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as ...

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers PR Newswire Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming dru...

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor PR Newswire Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and ...

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor PR Newswire – AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improv...

Mountain Valley MD Holdings Inc (MVMDF) is expected to report for quarter end 2024-12-31 Yunji Inc. (YJ) is expected to report for quarter end 2024-12-31 UpHealth Inc. (UPHL) is expected to report for quarter end 2024-12-31 Fisker Inc. Class A (FSRNQ) is expected to report for quarter...

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 PR Newswire TEL AVIV, Israel , April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharm...

2025-04-01 18:44:31 ET Galmed Pharmaceuticals Ltd. (GLMD) earnings is schedule to release on 2025-04-02. Following Earnnigs Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in GLMD stock price following earnings ha...

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy PR Newswire TEL AVIV, Israel , March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD)...